Lbmc Investment Advisors LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 13.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,075 shares of the biopharmaceutical company’s stock after selling 955 shares during the quarter. Lbmc Investment Advisors LLC’s holdings in Pfizer were worth $218,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the stock. Evolution Wealth Advisors LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $34,000. IMA Wealth Inc. grew its stake in shares of Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 477 shares during the last quarter. Financial Gravity Wealth Inc. grew its stake in shares of Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 257 shares during the last quarter. Vestor Capital LLC grew its stake in shares of Pfizer by 60.1% during the second quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 581 shares during the last quarter. Finally, HMS Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $71,000. 71.66% of the stock is owned by hedge funds and other institutional investors.
Shares of PFE stock opened at $36.39 on Friday. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47. The stock has a market cap of $203.38 billion, a PE ratio of 12.13, a PEG ratio of 2.18 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The firm’s 50 day moving average price is $36.30 and its two-hundred day moving average price is $39.54.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.96%. Pfizer’s payout ratio is presently 48.00%.
PFE has been the topic of several research analyst reports. Morgan Stanley decreased their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 27th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. UBS Group reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. Bank of America initiated coverage on shares of Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price target on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, September 19th. They noted that the move was a valuation call. Eleven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $44.47.
In other news, major shareholder Pfizer Inc bought 50,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Initial Coin Offerings entail a high degree of risk
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.